CHiR Therapy for Elderly DLBCL Intolerant to Chemo
ConditionDiffuse Large B-Cell Lymphoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age70-100
SponsorFirst Affiliated Hospital of Ningbo University
About this trial
The objective of exploring the application of CHiR is to evaluate its therapeutic efficacy and safety in newly diagnosed elderly patients with diffuse large B-cell lymphoma (DLBCL) aged 70 and above, and to investigate the genetic subtypes that may benefit from CHiR. The primary endpoint is the complete remission rate (CRR) at the end of 8 cycles.
Eligibility criteria
Qualifiers
Age ≥ 70 years;
ECOG score of 0-3;
Rated as unfit or frail on the simplified geriatric assessment (sGA);
Histologically confirmed CD20-positive diffuse large B-cell lymphoma (diagnostic criteria according to WHO 2016), excluding transformed type 2 DLBCL;
Disqualifiers
None
Trial design
Treatments tested in this trial
- CHiR-DEL
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov